<DOC> 
<DOCNO>1040124_business_story_2821459.utf8</DOCNO> 
<TEXT> 

The Telegraph - Calcutta : Business

 Saturday, January 24, 2004 
				 Ranbaxy profit takes a beating 

 OUR BUREAUX
																								Jan. 23: Pharma major Ranbaxy Laboratories reported a 9 per cent decline in net profit to Rs 175.8 crore compared with Rs 191.7 crore in the corresponding previous quarter. Total income increased to Rs 1,232.4 crore in the reporting quarter as against Rs 1, 139.30 crore in the year-ago period.
																								Ranbaxy had a windfall since March 2002 from selling a copy of the generic version of Glaxo SmithKline Plcs Ceftin antibiotic, as it faced no competition till July last year. However, now competition has hit its earnings, particularly when Watson Pharmaceuticals started selling a Ceftin copy developed by Lupin Ltd, said pharmaceutical industry sources.
																								Speaking at an audio conference with reporters, Brian Tempest, joint managing director and CEO designate, Ranbaxy, said, It is true that in US Ceftin sales has come down from 43 million to 5 million owing to competition.
																								This years fourth quarter net profit is showing a downturn also due to the fact that in the fourth quarter of last fiscal, the company had received a $6-million milestone payment from Bayer AG, Tempest added. 
																								For the full year, Ranbaxy posted a 14 per cent rise in net profit to Rs 739.3 crore (Rs 647 crore). Total income rose to Rs 4,872.9 crore (Rs 3, 932.4 crore). 
 ACC Q3 net up
																								Associated Cement Companies Ltd (ACC) has posted 10.4 per cent rise in net profit at Rs 22.32 crore for the third quarter ended December 31, 2003 as against Rs 20.21 crore in the same period last fiscal. Net income grew to Rs 789.32 crore as against Rs 727.92 crore year-on-year, the company informed the BSE today.
																								The board has approved a proposal to raise long-term funds to the tune of $100 million, through financial offerings and forms, which would be decided later, the company said.
 Tata Tea net dips
																								Tata Tea reported lower profit after tax at Rs 15.57 crore for the third quarter ended December 31, 2003 compared with Rs 16.97 crore achieved in the corresponding previous quarter. Total income rose to Rs 205.77 crore (Rs 193.09 crore).
																								In the nine-month period from April to December 2003, the company posted a profit after tax of Rs 72.86 crore (Rs 67.10 crore).
 Glaxo SmithKline net 
																								Glaxo SmithKline Consumer Healthcare Ltds net profit decline 10.18 per cent to Rs 76.35 crore for the year ended December 31, 2003, compared with Rs 85.01 crore posted in the year-ago period. Total revenues (net of excise) increased to Rs 818.55 crore (Rs 767.1 crore).

</TEXT> 
</DOC>